Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.

Fiche publication

Date publication

juillet 2025

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Roblin X, Vieujean S, Nancey S, Hebuterne X, Arab-Hocine N, Savoye G, Viennot S, Bouguen G, Fumery M, Duru G, Botelho-Nevers E, Berger AE, Tardy B, Mathieu N, Barrau M, Peyrin-Biroulet L, Paul S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40852895

Résumé

Pneumococcal vaccination is essential for patients with inflammatory bowel diseases (IBD), but its efficacy is reduced in those on antitumor necrosis factor (TNF) or immunosuppressive therapy. This study compared immune responses to standard versus intensified pneumococcal vaccination strategies in IBD patients receiving anti-TNF (±immunosuppressors) or vedolizumab.